BioCentury | May 30, 2020
Management Tracks

Schneyer named Acadia CBO; plus Hansa, MaaT, iOnctura, First Light, Oligomerix, Galecto and Hyloris

CNS disorders company Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) announced Mark Schneyer as its first CBO. He was VP, business development at the Upjohn unit of Pfizer Inc. (NYSE:PFE). Hansa Biopharma AB (SSE:HNSA) said Achim Kaufhold will...
BioCentury | May 28, 2020
Management Tracks

Quick departure for Semerjian as Immunomedics CEO; plus Ziopharm, Kinnate, Applied Therapeutics, Relmada, AskBio and more

Less than two months after becoming president and CEO of Immunomedics Inc. (NASDAQ:IMMU), Harout Semerjian is stepping down because of “unfortunate significant logistical obstacles presented by the COVID-19 pandemic,” according to the cancer company. Executive...
BioCentury | May 9, 2020
Management Tracks

O’Connor joins TG Therapeutics as CSO; plus changes at FogPharma, Gemini, Dicerna, Akcea and more

Cancer and autoimmune company TG Therapeutics Inc. (NASDAQ:TGTX) hired Owen O’Connor as CSO. He was director of the Center for Lymphoid Malignancies at Columbia University Medical Center.   RNAi company Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) said...
BC Extra | Nov 22, 2019
Preclinical News

Nov. 21 Preclinical Quick Takes: Excision applies CRISPR editing to herpes, John Cunningham viruses; plus Caribou, Oligomerix, Kymab and Gladstone-Boston Univer

Excision targets CRISPR to herpes, JC viruses  Excision BioTherapeutics Inc. and collaborators at Temple University presented a pair of posters at the International Symposium on NeuroVirology meeting in Atlanta showing CRISPR-Cas9 gene editing could treat...
BC Week In Review | Dec 16, 2013
Company News

Oligomerix, Taconic Farms deal

Taconic and Oligomerix partnered to evaluate the utility of a microtubule-associated protein tau (MAPT; tau; FTDP-17 ) mouse model (JNPL3) from Taconic as a tool for preclinical testing of compounds for Alzheimer's disease. Oligomerix will use...
BC Week In Review | May 27, 2013
Financial News

Oligomerix completes venture financing

Oligomerix Inc. , New York, N.Y.   Business: Neurology   Date completed: 5/22/13   Type: Venture financing   Raised: $2.8 million   Investors: New investors; existing investors   Note: The amount includes convertible preferred shares and...
BC Week In Review | Apr 30, 2012
Financial News

Oligomerix completes venture financing

Oligomerix Inc. , New York, N.Y.   Business: Neurology   Date completed: 4/23/12   Type: Venture financing   Raised: $2 million   Investors: Wheatley MedTech Partners; Wheatley New York Partners; Durand Venture Associates  ...
BioCentury | Jan 3, 2011
Strategy

Biogen's aggregation play

Biogen Idec Inc. 's purchase of three preclinical mAbs from Neurimmune Therapeutics AG is a bet on a new theory of neurodegenerative disease in which extracellular forms of aggregated proteins spread disease throughout the brain,...
BC Week In Review | Oct 18, 2010
Company News

Oligomerix management update

Oligomerix Inc. , New York, N.Y.   Business: Neurology   Hired: Jack Pasini as a director and CCO, formerly VP of worldwide marketing for the anti-infective and allergy/respiratory therapeutic groups at Pfizer Inc.  ...
BC Week In Review | Oct 18, 2010
Company News

Oligomerix board of directors update

Oligomerix Inc. , New York, N.Y.   Business: Neurology   Appointed: Vic Micati, a director, as chairman  ...
Items per page:
1 - 10 of 13
BioCentury | May 30, 2020
Management Tracks

Schneyer named Acadia CBO; plus Hansa, MaaT, iOnctura, First Light, Oligomerix, Galecto and Hyloris

CNS disorders company Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) announced Mark Schneyer as its first CBO. He was VP, business development at the Upjohn unit of Pfizer Inc. (NYSE:PFE). Hansa Biopharma AB (SSE:HNSA) said Achim Kaufhold will...
BioCentury | May 28, 2020
Management Tracks

Quick departure for Semerjian as Immunomedics CEO; plus Ziopharm, Kinnate, Applied Therapeutics, Relmada, AskBio and more

Less than two months after becoming president and CEO of Immunomedics Inc. (NASDAQ:IMMU), Harout Semerjian is stepping down because of “unfortunate significant logistical obstacles presented by the COVID-19 pandemic,” according to the cancer company. Executive...
BioCentury | May 9, 2020
Management Tracks

O’Connor joins TG Therapeutics as CSO; plus changes at FogPharma, Gemini, Dicerna, Akcea and more

Cancer and autoimmune company TG Therapeutics Inc. (NASDAQ:TGTX) hired Owen O’Connor as CSO. He was director of the Center for Lymphoid Malignancies at Columbia University Medical Center.   RNAi company Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) said...
BC Extra | Nov 22, 2019
Preclinical News

Nov. 21 Preclinical Quick Takes: Excision applies CRISPR editing to herpes, John Cunningham viruses; plus Caribou, Oligomerix, Kymab and Gladstone-Boston Univer

Excision targets CRISPR to herpes, JC viruses  Excision BioTherapeutics Inc. and collaborators at Temple University presented a pair of posters at the International Symposium on NeuroVirology meeting in Atlanta showing CRISPR-Cas9 gene editing could treat...
BC Week In Review | Dec 16, 2013
Company News

Oligomerix, Taconic Farms deal

Taconic and Oligomerix partnered to evaluate the utility of a microtubule-associated protein tau (MAPT; tau; FTDP-17 ) mouse model (JNPL3) from Taconic as a tool for preclinical testing of compounds for Alzheimer's disease. Oligomerix will use...
BC Week In Review | May 27, 2013
Financial News

Oligomerix completes venture financing

Oligomerix Inc. , New York, N.Y.   Business: Neurology   Date completed: 5/22/13   Type: Venture financing   Raised: $2.8 million   Investors: New investors; existing investors   Note: The amount includes convertible preferred shares and...
BC Week In Review | Apr 30, 2012
Financial News

Oligomerix completes venture financing

Oligomerix Inc. , New York, N.Y.   Business: Neurology   Date completed: 4/23/12   Type: Venture financing   Raised: $2 million   Investors: Wheatley MedTech Partners; Wheatley New York Partners; Durand Venture Associates  ...
BioCentury | Jan 3, 2011
Strategy

Biogen's aggregation play

Biogen Idec Inc. 's purchase of three preclinical mAbs from Neurimmune Therapeutics AG is a bet on a new theory of neurodegenerative disease in which extracellular forms of aggregated proteins spread disease throughout the brain,...
BC Week In Review | Oct 18, 2010
Company News

Oligomerix management update

Oligomerix Inc. , New York, N.Y.   Business: Neurology   Hired: Jack Pasini as a director and CCO, formerly VP of worldwide marketing for the anti-infective and allergy/respiratory therapeutic groups at Pfizer Inc.  ...
BC Week In Review | Oct 18, 2010
Company News

Oligomerix board of directors update

Oligomerix Inc. , New York, N.Y.   Business: Neurology   Appointed: Vic Micati, a director, as chairman  ...
Items per page:
1 - 10 of 13